Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.

The aim of this meta-analysis was to analyze the efficacy and safety of antidepressants for the treatment of irritable bowel syndrome.We searched MEDLINE, EMBASE, Scopus and The Cochrane Library for randomized controlled trials investigating the efficacy and safety of antidepressants in the treatmen...

Full description

Bibliographic Details
Main Authors: Chen Xie, Yurong Tang, Yunfeng Wang, Ting Yu, Yun Wang, Liuqin Jiang, Lin Lin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4529302?pdf=render
_version_ 1811305731177054208
author Chen Xie
Yurong Tang
Yunfeng Wang
Ting Yu
Yun Wang
Liuqin Jiang
Lin Lin
author_facet Chen Xie
Yurong Tang
Yunfeng Wang
Ting Yu
Yun Wang
Liuqin Jiang
Lin Lin
author_sort Chen Xie
collection DOAJ
description The aim of this meta-analysis was to analyze the efficacy and safety of antidepressants for the treatment of irritable bowel syndrome.We searched MEDLINE, EMBASE, Scopus and The Cochrane Library for randomized controlled trials investigating the efficacy and safety of antidepressants in the treatment of irritable bowel syndrome. Article quality was evaluated by Jadad score. RevMan 5.0 and Stata 12.0 were used for the meta-analysis.Twelve randomized controlled trials were included in this study and most of these trials were of high quality (Jadad score ≥4). Five articles focused on tricyclic antidepressants, six articles involved selective serotonin reuptake inhibitors, and one article investigated both types of treatment. The pooled risk ratio showed antidepressant treatment can improve global symptoms (RR = 1.38, 95% CI 1.08, 1.77). In the subgroup analysis, treatment with tricyclic antidepressants showed an improvement in global symptoms (RR = 1.36, 95% CI 1.07, 1.71), while treatment with selective serotonin reuptake inhibitors showed no statistically significant difference in global symptoms compared with the control groups (RR = 1.38, 95% CI 0.83, 2.28). The pooled risk ratio of dropout due to side effects following antidepressant treatment was 1.71 with 95% CI (0.98, 2.99). The subgroup analysis showed the pooled risk ratio of dropout in the tricyclic antidepressants group was 1.92 with 95% CI (0.89, 4.17). In the selective serotonin reuptake inhibitors group, the pooled risk ratio of dropout was 1.5 with 95% CI (0.67, 3.37). Selective serotonin reuptake inhibitors showed no benefit in alleviating abdominal pain and improving quality of life. There was no difference in the incidence of common adverse events between treatment and control groups.TCAs can improve global symptoms of irritable bowel syndrome, while there was no strong evidence to confirm the effectiveness of SSRIs for the treatment of IBS.
first_indexed 2024-04-13T08:31:44Z
format Article
id doaj.art-e95553fc5c2c42ce95a1fdf491944a80
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-13T08:31:44Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-e95553fc5c2c42ce95a1fdf491944a802022-12-22T02:54:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e012781510.1371/journal.pone.0127815Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.Chen XieYurong TangYunfeng WangTing YuYun WangLiuqin JiangLin LinThe aim of this meta-analysis was to analyze the efficacy and safety of antidepressants for the treatment of irritable bowel syndrome.We searched MEDLINE, EMBASE, Scopus and The Cochrane Library for randomized controlled trials investigating the efficacy and safety of antidepressants in the treatment of irritable bowel syndrome. Article quality was evaluated by Jadad score. RevMan 5.0 and Stata 12.0 were used for the meta-analysis.Twelve randomized controlled trials were included in this study and most of these trials were of high quality (Jadad score ≥4). Five articles focused on tricyclic antidepressants, six articles involved selective serotonin reuptake inhibitors, and one article investigated both types of treatment. The pooled risk ratio showed antidepressant treatment can improve global symptoms (RR = 1.38, 95% CI 1.08, 1.77). In the subgroup analysis, treatment with tricyclic antidepressants showed an improvement in global symptoms (RR = 1.36, 95% CI 1.07, 1.71), while treatment with selective serotonin reuptake inhibitors showed no statistically significant difference in global symptoms compared with the control groups (RR = 1.38, 95% CI 0.83, 2.28). The pooled risk ratio of dropout due to side effects following antidepressant treatment was 1.71 with 95% CI (0.98, 2.99). The subgroup analysis showed the pooled risk ratio of dropout in the tricyclic antidepressants group was 1.92 with 95% CI (0.89, 4.17). In the selective serotonin reuptake inhibitors group, the pooled risk ratio of dropout was 1.5 with 95% CI (0.67, 3.37). Selective serotonin reuptake inhibitors showed no benefit in alleviating abdominal pain and improving quality of life. There was no difference in the incidence of common adverse events between treatment and control groups.TCAs can improve global symptoms of irritable bowel syndrome, while there was no strong evidence to confirm the effectiveness of SSRIs for the treatment of IBS.http://europepmc.org/articles/PMC4529302?pdf=render
spellingShingle Chen Xie
Yurong Tang
Yunfeng Wang
Ting Yu
Yun Wang
Liuqin Jiang
Lin Lin
Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.
PLoS ONE
title Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.
title_full Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.
title_fullStr Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.
title_full_unstemmed Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.
title_short Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis.
title_sort efficacy and safety of antidepressants for the treatment of irritable bowel syndrome a meta analysis
url http://europepmc.org/articles/PMC4529302?pdf=render
work_keys_str_mv AT chenxie efficacyandsafetyofantidepressantsforthetreatmentofirritablebowelsyndromeametaanalysis
AT yurongtang efficacyandsafetyofantidepressantsforthetreatmentofirritablebowelsyndromeametaanalysis
AT yunfengwang efficacyandsafetyofantidepressantsforthetreatmentofirritablebowelsyndromeametaanalysis
AT tingyu efficacyandsafetyofantidepressantsforthetreatmentofirritablebowelsyndromeametaanalysis
AT yunwang efficacyandsafetyofantidepressantsforthetreatmentofirritablebowelsyndromeametaanalysis
AT liuqinjiang efficacyandsafetyofantidepressantsforthetreatmentofirritablebowelsyndromeametaanalysis
AT linlin efficacyandsafetyofantidepressantsforthetreatmentofirritablebowelsyndromeametaanalysis